Author： Gallego Juan A Nielsen Jimmi De Hert Marc Kane John M Correll Christoph U
Publisher： Informa Healthcare
ISSN： 1474-0338
Source： Expert Opinion on Drug Safety, Vol.11, Iss.4, 2012-07, pp. : 527-542
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Current Pharmaceutical Design, Vol. 10, Iss. 18, 2004-07 ,pp. :
Access to resources
Recommend
Antipsychotic polypharmacy in schizophrenia in Canada
Inpharma, Vol. 1, Iss. 1296, 2001-01 ,pp. :
Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks
By Barnes Thomas R.E. Paton Carol
CNS Drugs, Vol. 25, Iss. 5, 2011-05 ,pp. :
Antipsychotic polypharmacy determined by severity of psychosis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 494, 2006-01 ,pp. :
Haematological safety of antipsychotic drugs
By Hall RL Smith AG Edwards J Guy
Expert Opinion on Drug Safety, Vol. 2, Iss. 4, 2003-07 ,pp. :